Vanderbilt Study Shows Sharp Decline in Cardiac Device Infections With TYRX® AIGISRx® Antibacterial Envelope

Published: Dec 19, 2012

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--In the first bullet point of the key findings, this release copy corrects a previously erroneous p-value, which should read p=0.04 and not p=0.4. Patients at high risk for surgical site infection following Cardiac Implantable Electronic Device (CIED) implantation with TYRX, Inc.’s AIGISRx Antibacterial Envelope experienced significantly reduced risk of device infection compared to patients implanted without AIGISRx. Results of a retrospective cohort study of CIED implantations, including pacemakers and implantable defibrillators, were published online in the journal of Pacing and Clinical Electrophysiology (PACE). Matthew J. Kolek, MD, William F. Dresen, MD, Quinn S. Wells, MD, and Christopher R. Ellis, MD, from the Vanderbilt Heart and Vascular Institute, conducted the study of surgical site infections following pacemaker or implantable cardioverter defibrillator (ICD) implantation.

Back to news